6-氯咪唑并[1,2-b]哒嗪-3-甲腈的合成研究

doi:10.3976/j.issn.1002-4026.2021.01.013

山东科学 ›› 2021, Vol. 34 ›› Issue (1): 105-112.doi: 10.3976/j.issn.1002-4026.2021.01.013

6-氯咪唑并[1,2-b]哒嗪-3-甲腈的合成研究

程伟¹，陈启绪¹，张向龙²，祁祺1，王明君¹，刘圣玮¹，袁文鹏^1*

1.齐鲁工业大学（山东省科学院）山东省科学院菏泽分院山东省生物工程技术创新中心，山东菏泽 274000; 2.山东友帮生化科技有限公司山东省小分子杂环化合物工程实验室，山东菏泽 274000

收稿日期:2020-10-09 出版日期:2021-02-15 发布日期:2021-01-31
基金资助:
山东省重点研发计划（2018CXJJA1060 010）

Synthesis of 6-chloroimidazo[1,2-b]pyrazine-3-carbonitrile

CHENG Wei¹，CHEN Qi-xu¹，ZHANG Xiang-long²，QI Qi¹，WANG Ming-jun¹， LIU Sheng-wei¹，YUAN Wen-peng^1*

1. Biological Engineering Technology Innovation Center of Shandong Province，Heze Branch，Qilu University of Technology (Shandong Academy of Sciences)， Heze 274000， China；2. Shandong Engineering Laboratory of Small Molecule Heterocyclic Compounds，Shandong Youbang Biochemical Technology Co., Ltd.,Heze 274000,China

Received:2020-10-09 Online:2021-02-15 Published:2021-01-31

摘要/Abstract

摘要： 6-氯咪唑并[1,2-b]哒嗪-3-甲腈是抗癌新药新型TGF-β R1抑制剂BMS-986260的关键中间体。以水合肼和马来酸酐为起始原料,在酸催化下发生缩合反应，再用三氯氧磷进行氯化，与氨水发生氨解反应，接着与N,N-二甲基甲酰胺二甲基缩醛进行亚胺化反应，最后与溴乙腈发生关环缩合共5步反应合成。总收率为69.4%，产品经高效液相色谱（HPLC）紫外检测（波长254 nm）纯度为98.3%。产物结构经 ¹H NMR、¹³C NMR 确证。与已有的文献方法相比较，报道的合成路线具有化学选择性好、成本低廉、操作简便、收率高、避免柱层析分离、适合工业化生产的特点。

关键词: 水合肼, 马来酸酐, 6-氯咪唑并[1,2-b]哒嗪-3-甲腈, 合成路线

Abstract: 6-chloroimidazo[1,2-b]pyrazine-3-carbonitrile is a major intermediate of BMS-986260, which is a novel TGF-β R1 inhibitor that can be used as an anticancer drug. The synthesis goes through the following five-step reaction process with a total yield of 69.4%: hydrazine hydrate and maleic anhydride are considered as raw materials, acid-catalyzed condensation reaction, chlorination with phosphorus oxychloride, ammonolysis with ammonia water, imidization with N,N-dimethylformamide dimethyl acetal, and ring-closing condensation with bromoacetonitrile. The purity of the obtained product was 98.3%, which was measured via high-performance liquid chromatography (HPLC) at wavelength of 254 nm. The structure was confirmed through ¹H NMR and ¹³C NMR. Compared with the reported synthetic routes, this route exhibits good chemical selectivity, low cost, easy operation, and high yield. Further, it requires no column chromatography separation and is suitable for industrial production.

Key words: hydrazine hydrate, maleic anhydride; 6-chloroimidazo[1,2-b]pyrazine-3-carbonitrile, synthesis route

中图分类号:

R914.5

程伟, 陈启绪, 张向龙, 祁祺, 王明君, 刘圣玮, 袁文鹏. 6-氯咪唑并[1,2-b]哒嗪-3-甲腈的合成研究[J]. 山东科学, 2021, 34(1): 105-112.

CHENG Wei, CHEN Qi-xu, ZHANG Xiang-long, QI Qi, WANG Ming-jun, LIU Sheng-wei, YUAN Wen-peng. Synthesis of 6-chloroimidazo[1,2-b]pyrazine-3-carbonitrile[J]. Shandong Science, 2021, 34(1): 105-112.

参考文献 15

1	LE CLAIRE M, DIEGO G C, FREDERIC D, et al. Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a soft focus kinase library: part 1[J]. Journal of Medicinal Chemistry, 2014, 57(6): 2789-2798. doi: 10.1021/jm500098s
2	FUSHIMI M, FUJIMORI I, WAKABAYASHI T, et al. Discovery of potent, selective, and brain-penetrant 1 H-Pyrazol-5-yl-1 H-pyrrolo[2,3- B]pyridines as anaplastic lymphoma kinase (ALK) inhibitors[J]. Journal of Medicinal Chemistry, 2019, 62(10): 4915-4935. doi: 10.1021/acs.jmedchem.8b01630
3	MATSUMOTO S, MIYAMOTO N, HIRAYAMA T, et al. Structure-based design, synthesis, and evaluation of imidazo [1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors[J]. Bioorganic Medicinal Chemistry, 2013, 21(24): 7686-7698. doi: 10.1016/j.bmc.2013.10.028
4	KIM S, BANG G, PARK C, et al.Prearation of fused pyridazine derivative with FMS kinase inhibitory activity for treatment of inflammatory diseases:Korea,KR2014086002 [P]. 2014-7-18.
5	FAN Y, LOREN J, MOLTENI V, et al.Preparation of imidazopyridazine derivatives for use as TRK inhibitors: USA,WO2012034091 [P]. 2012-4-15.
6	KOBE J, STANOVNIK B, TISLER T, et al. Synthesis of pyridazine derivatives. XV. some electrophilic substitutions on imidazo[1,2-b]pyridazines[J]. Tetrahedron, 1968, 24(1): 239-245. doi: 10.1016/0040-4020(68)89024-6
7	唐波，傅榕赓，盛文兵，等. PDE-4 抑制剂的研究进展 [J]. 化学试剂, 2015, 37 (9): 803-808. doi: 10.13822/j.cnki.hxsj.2015.09.008
8	KINSELLA T,GELMAN M,HONG H, et al.Preparation of imidazole and thiazole compounds as TGF-β inhibitors: USA,WO2016140884 [P]. 2016-9-9.
9	VELAPARTHI U, DARNE C P, WARRIER J, et al. Discovery of BMS-986260, a potent, selective, and orally bioavailable TGFβR1 inhibitor as an immuno-oncology agent[J]. ACS Medicinal Chemistry Letters, 2020, 11(2): 172-178. doi: 10.1021/acsmedchemlett.9b00552
10	GOODFELLOW S, NGUYEN X, RAVULA B, et al. Preparation of imidazopyridine compounds as mixed lineage kinase inhibitors: USA,US20140256733 [P]. 2014-9-11.
11	桑晓宏，王昊，游雪甫，等. 靶向 TGF-β 及受体的小分子抑制剂研究进展 [J]. 药学学报, 2019, 54 (9): 1538-1546. doi: 10.16438/j.0513-4870.2019-0132
12	FAN H L, LI F H. Convenient two-step one-pot synthesis of 3-substituted imidazo[1, 2-a]pyridines and imidazo[1, 2-b]pyridazines[J]. Journal of Chemical Sciences, 2018, 130(5): 1-8. doi: 10.1007/s12039-018-1462-z
13	FEUER H, WHITE E H, WYMAN J E. The reactions of maleic anhydride with hydrazine Hydrate1[J]. Journal of the American Chemical Society, 1958, 80(14): 3790-3792. doi: 10.1021/ja01547a081
14	MIZZONI R, SPOERRI P. Synthesis in the pyridazine series. I. pyridazine and 3,6-dichloropyridazine［J］. Journal of the American Chemical Society, 1951, 73(6): 1873-1874. doi: 10.1021/ja01148a537
15	康从民，张德华，吕英涛. 6-氯咪唑并［1,2-b］哒嗪的合成［J］. 化学与生物工程, 2009, 26(12): 25-27. doi: 10.3969/j.issn.1672-5425.2009.12.006

6-氯咪唑并[1,2-b]哒嗪-3-甲腈的合成研究

Synthesis of 6-chloroimidazo[1,2-b]pyrazine-3-carbonitrile

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献 15

相关文章 0

Metrics

本文评价

推荐阅读 0